Patents

US9822126: Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof

The invention relates to new generation of triazole functionality containing 6-nitro-2,3-dihydroimidazooxazole agents for general formula I, their method of preparation and their use as drugs for treatment of tuberculosis, MDR-TB and XDR-TB either alone or in combination with other anti-tubercular agents. In general formula 1, X is selected from a group (CH2)n or a direct bond, where n is any number from 1-6, Y is selected from O, S or direct bond, R1 is selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, biaryl, substituted biaryl, heterocyclic and substituted heterocyclic, wherein the substituted heterocyclic is selected from any of the following rings consisting of piperazinyl, morpholinyl, piperidyl, pyridyl, triazolyl, triazinyl, pyrimidinyl, pyridazinyl, oxazolyl, furanyl, benzofuranyl, thiophenyl, pyrrolyl, imidazoyl, thiazoyl, quinolinyl, isoquinolinyl, benzooxazolyl and benzothiazolyl and the substitution on aryl and biaryl is selected from the group consisting of F, CI, Br, I, CF3, OCF3, OR11, NO2 and alkyl chain from C1 to C14, wherein R11 is selected from the group consisting of H, alkyl, phenyl and substituted phenyl.

Filing Date: 20-04-2017

Issue Date: 21-11-2017

Applicant: CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu

Patent No: US9822126

Application No: 15/520799

Inventor(s): Yempalla Kushalava Reddy; Munagala Gurunadham; Singh Samsher; Sharma Sumit; Khan Inshad Ali; Vishwakarma Ram Asrey; Singh Parvinder Pal

IPC Classification: A61K 31/424, C07D 498/04

Country: United States of America

Related Patents